Bausch And Lomb Inc Drug Patent Portfolio
Bausch And Lomb Inc owns 9 orange book drugs protected by 40 US patents with Lotemax having the least patent protection, holding only 1 patent. And Xiidra with maximum patent protection, holding 16 patents. Given below is the list of Bausch And Lomb Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10507132 | Topical administration method | 21 Jun, 2037 | Active |
| US10596107 | Ophthalmic suspension composition | 23 Dec, 2036 | Active |
| US11357738 | Semifluorinated compounds and their compositions | 29 Sep, 2036 | Active |
| US11534395 | Ophthalmic suspension composition | 26 Jan, 2036 | Active |
| US9937075 | Apparatus and methods for ocular injection | 02 May, 2034 | Active |
| US11058677 | LFA-1 inhibitor formulations | 18 Dec, 2033 | Active |
| US9636332 | Methods and devices for the treatment of ocular diseases in human subjects | 08 Nov, 2033 | Active |
| US10058615 | Semifluorinated alkane compositions | 12 Sep, 2033 | Active |
| US10369117 | Compositions comprising mixtures of semifluorinated alkanes | 12 Sep, 2033 | Active |
| US10449164 | Methods of treating ocular disorders using semifluorinated alkanes | 12 Sep, 2033 | Active |
| US10576154 | Semifluorinated alkane compositions | 12 Sep, 2033 | Active |
| US9085553 | LFA-1 inhibitor and methods of preparation and polymorph thereof | 25 Jul, 2033 | Active |
| US8927574 | Crystalline pharmaceutical and methods of preparation and use thereof | 12 Nov, 2030 | Active |
| US9353088 | Crystalline pharmaceutical and methods of preparation and use thereof | 21 Oct, 2030 | Active |
| US9890141 | Crystalline pharmaceutical and methods of preparation and use thereof | 21 Oct, 2030 | Active |
| US8293742 | Preferential vasoconstriction compositions and methods of use | 14 Jul, 2030 | Active |
| US9259425 | Compositions and methods for eye whitening | 14 Jul, 2030 | Active |
| US11596600 | Vasoconstriction compositions and methods of use | 27 Jul, 2029 | Active |
| US11833245 | Vasoconstriction compositions and methods of use | 27 Jul, 2029 | Active |
| US8168655 | Compositions and methods for treatment of eye disorders | 09 May, 2029 | Active |
| US8367701 | Crystalline pharmaceutical and methods of preparation and use thereof | 15 Apr, 2029 | Active |
| US9447077 | Crystalline pharmaceutical and methods of preparation and use thereof | 15 Apr, 2029 | Active |
| US8636713 | Methods and devices for drug delivery to ocular tissue using microneedle | 02 May, 2027 | Active |
| US8084047 | Compositions and methods for treatment of eye disorders | 17 May, 2026 | Active |
| US8592450 | Compositions and methods for treatment of eye disorders | 17 May, 2026 | Active |
| US7314938 | Modulators of cellular adhesion | 10 Mar, 2025 | Active |
| US8784789 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | 13 Jan, 2025 | Active |
| US10124000 | Modulators of cellular adhesion | 05 Nov, 2024 | Expired |
| US7745460 | Modulators of cellular adhesion | 05 Nov, 2024 | Expired |
| US7790743 | Modulators of cellular adhesion | 05 Nov, 2024 | Expired |
| US7928122 | Modulators of cellular adhesion | 05 Nov, 2024 | Expired |
| US9216174 | Modulators of cellular adhesion | 05 Nov, 2024 | Expired |
| US8877168 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | 30 Jul, 2023 | Expired |
| US6780877 | Acid addition salt of optically active piperidine compound and process for preparing the same | 19 Sep, 2019 | Expired |
| US5800807 | Ophthalmic compositions including glycerin and propylene glycol | 29 Jan, 2017 | Expired |
| US6011020 | Nucleic acid ligand complexes | 04 Jan, 2017 | Expired |
| US5932462 | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces | 03 Aug, 2016 | Expired |
| US6051698 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | 19 May, 2015 | Expired |
| US5919455 | Non-antigenic branched polymer conjugates | 27 Oct, 2013 | Expired |
| US6113906 | Water-soluble non-antigenic polymer linkable to biologically active material | 27 Oct, 2013 | Expired |
Latest Legal Activities on Bausch And Lomb Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bausch And Lomb Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 02 Jul, 2024 | US7314938 |
|
Withdrawal of Application for PTE
Critical
| 02 Jul, 2024 | US8168655 |
|
Withdrawal of Application for PTE
Critical
| 02 Jul, 2024 | US8084047 |
|
Withdrawal of Application for PTE
Critical
| 02 Jul, 2024 | US8592450 |
|
Withdrawal of Application for PTE
Critical
| 02 Jul, 2024 | US7790743 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US8293742 |
| Petition Requesting Trial | 15 Mar, 2024 | US11596600 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2024 | US9447077 |
| Petition Requesting Trial | 15 Feb, 2024 | US11833245 |
| Paralegal TD Not accepted | 14 Feb, 2024 | US7314938 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US11357738 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10449164 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10058615 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10576154 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10369117 |
Bausch And Lomb Inc's Drug Patent Litigations
Bausch And Lomb Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2006, against patent number US6113906. The petitioner , challenged the validity of this patent, with RICHARD B. GREENWALD et al as the respondent. Click below to track the latest information on how companies are challenging Bausch And Lomb Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11596600 | February, 2024 | Pending | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US11833245 | January, 2024 |
Trial Instituted
(13 Aug, 2024)
| Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US8293742 | November, 2021 |
Final Written Decision - Appealed
(15 May, 2023)
| Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US9259425 | November, 2021 |
Terminated-Settled
(05 Oct, 2022)
| Eye Therapies, LLC | Slayback Pharma LLC |
| US10596107 | January, 2019 |
Decision
(18 Jul, 2019)
| Mohannad Shawer et al. | |
| US10449164 | April, 2018 |
Decision
(17 Jan, 2019)
| Novaliq GmbH | |
| US8877168 | June, 2016 |
Terminated-Settled
(14 Nov, 2016)
| Senju Pharmaceuticals Co., Ltd. | Mylan Pharmaceuticals, Inc. |
| US8784789 | February, 2016 |
Terminated-Settled
(31 Aug, 2016)
| Senju Pharmaceutical Co. Ltd. | Mylan Pharmaceuticals, Inc. |
| US6113906 | October, 2006 |
Decision
(05 Oct, 2006)
| RICHARD B. GREENWALD et al | |
Bausch And Lomb Inc Drug Patents' Oppositions Filed in EPO
Bausch And Lomb Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 04, 2019, by Allergan, Inc.. This opposition was filed on patent number EP16704744A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP20166312A | Feb, 2023 | SANDOZ AG | Granted and Under Opposition |
| EP14791646A | Mar, 2022 | European Oppositions Limited | Granted and Under Opposition |
| EP18209003A | Dec, 2020 | Sandoz AG | Granted and Under Opposition |
| EP16704744A | Sep, 2019 | Breuer, Markus | Revoked |
| EP16704744A | Sep, 2019 | European Oppositions Limited | Revoked |
| EP16704744A | Sep, 2019 | ALLERGAN, INC. | Revoked |
Bausch And Lomb Inc's Family Patents
Bausch And Lomb Inc Drug List
Given below is the complete list of Bausch And Lomb Inc's drugs and the patents protecting them.
1. Bepreve
Bepreve is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8784789 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
13 Jan, 2025
(a month from now)
| Active |
| US8877168 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
30 Jul, 2023
(1 year, 3 months ago)
| Expired |
| US6780877 | Acid addition salt of optically active piperidine compound and process for preparing the same |
19 Sep, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bepreve's drug page
2. Lotemax
Lotemax is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5800807 | Ophthalmic compositions including glycerin and propylene glycol |
29 Jan, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax's drug page
3. Lotemax Sm
Lotemax Sm is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10596107 | Ophthalmic suspension composition |
23 Dec, 2036
(12 years from now)
| Active |
| US11534395 | Ophthalmic suspension composition |
26 Jan, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax Sm's drug page
4. Lumify
Lumify is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8293742 | Preferential vasoconstriction compositions and methods of use |
14 Jul, 2030
(5 years from now)
| Active |
| US9259425 | Compositions and methods for eye whitening |
14 Jul, 2030
(5 years from now)
| Active |
| US11596600 | Vasoconstriction compositions and methods of use |
27 Jul, 2029
(4 years from now)
| Active |
| US11833245 | Vasoconstriction compositions and methods of use |
27 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumify's drug page
5. Lumify Preservative Free
Lumify Preservative Free is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8293742 | Preferential vasoconstriction compositions and methods of use |
14 Jul, 2030
(5 years from now)
| Active |
| US9259425 | Compositions and methods for eye whitening |
14 Jul, 2030
(5 years from now)
| Active |
| US11596600 | Vasoconstriction compositions and methods of use |
27 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumify Preservative Free's drug page
Explore Our Curated Drug Screens
6. Macugen
Macugen is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6011020 | Nucleic acid ligand complexes |
04 Jan, 2017
(7 years ago)
| Expired |
| US5932462 | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
03 Aug, 2016
(8 years ago)
| Expired |
| US6051698 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
19 May, 2015
(9 years ago)
| Expired |
| US5919455 | Non-antigenic branched polymer conjugates |
27 Oct, 2013
(11 years ago)
| Expired |
| US6113906 | Water-soluble non-antigenic polymer linkable to biologically active material |
27 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Macugen's drug page
7. Miebo
Miebo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10507132 | Topical administration method |
21 Jun, 2037
(12 years from now)
| Active |
| US11357738 | Semifluorinated compounds and their compositions |
29 Sep, 2036
(11 years from now)
| Active |
| US10058615 | Semifluorinated alkane compositions |
12 Sep, 2033
(8 years from now)
| Active |
| US10369117 | Compositions comprising mixtures of semifluorinated alkanes |
12 Sep, 2033
(8 years from now)
| Active |
| US10449164 | Methods of treating ocular disorders using semifluorinated alkanes |
12 Sep, 2033
(8 years from now)
| Active |
| US10576154 | Semifluorinated alkane compositions |
12 Sep, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miebo's drug page
8. Xiidra
Xiidra is protected by 16 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11058677 | LFA-1 inhibitor formulations |
18 Dec, 2033
(9 years from now)
| Active |
| US9085553 | LFA-1 inhibitor and methods of preparation and polymorph thereof |
25 Jul, 2033
(8 years from now)
| Active |
| US8927574 | Crystalline pharmaceutical and methods of preparation and use thereof |
12 Nov, 2030
(5 years from now)
| Active |
| US9353088 | Crystalline pharmaceutical and methods of preparation and use thereof |
21 Oct, 2030
(5 years from now)
| Active |
| US9890141 | Crystalline pharmaceutical and methods of preparation and use thereof |
21 Oct, 2030
(5 years from now)
| Active |
| US8168655 | Compositions and methods for treatment of eye disorders |
09 May, 2029
(4 years from now)
| Active |
| US8367701 | Crystalline pharmaceutical and methods of preparation and use thereof |
15 Apr, 2029
(4 years from now)
| Active |
| US9447077 | Crystalline pharmaceutical and methods of preparation and use thereof |
15 Apr, 2029
(4 years from now)
| Active |
| US8084047 | Compositions and methods for treatment of eye disorders |
17 May, 2026
(1 year, 5 months from now)
| Active |
| US8592450 | Compositions and methods for treatment of eye disorders |
17 May, 2026
(1 year, 5 months from now)
| Active |
| US7314938 | Modulators of cellular adhesion |
10 Mar, 2025
(3 months from now)
| Active |
| US10124000 | Modulators of cellular adhesion |
05 Nov, 2024
(16 days ago)
| Expired |
| US7745460 | Modulators of cellular adhesion |
05 Nov, 2024
(16 days ago)
| Expired |
| US7790743 | Modulators of cellular adhesion |
05 Nov, 2024
(16 days ago)
| Expired |
| US7928122 | Modulators of cellular adhesion |
05 Nov, 2024
(16 days ago)
| Expired |
| US9216174 | Modulators of cellular adhesion |
05 Nov, 2024
(16 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xiidra's drug page
9. Xipere
Xipere is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9937075 | Apparatus and methods for ocular injection |
02 May, 2034
(9 years from now)
| Active |
| US9636332 | Methods and devices for the treatment of ocular diseases in human subjects |
08 Nov, 2033
(8 years from now)
| Active |
| US8636713 | Methods and devices for drug delivery to ocular tissue using microneedle |
02 May, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xipere's drug page